公开(公告)号：US20220249482A1

公开(公告)日：2022-08-11

申请号：US17675917

申请日：2022-02-18

Applicant: Korea Research Institute of Chemical Technology

Inventor： Kwangho Lee ,  Inji Shin ,  Gildon Choi ,  Chong Hak Chae ,  Hyeon Jeong Choe ,  Myoung Eun Jung ,  Byeong Uk Jeon ,  Byoung Chul Cho ,  Chae Won Park ,  Hwan Kim ,  Krishna Babu Duggirala

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

公开(公告)号：US11253516B2

公开(公告)日：2022-02-22

申请号：US16622057

申请日：2018-06-12

Applicant: Korea Research Institute of Chemical Technology

Inventor： Kwangho Lee ,  Inji Shin ,  Gildon Choi ,  Chong Hak Chae ,  Hyeon Jeong Choe ,  Myoung Eun Jung ,  Byeong Uk Jeon ,  Byoung Chul Cho ,  Chae Won Park ,  Hwan Kim ,  Krishna Babu Duggirala

IPC: A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D413/12 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

公开(公告)号：US20200179384A1

公开(公告)日：2020-06-11

申请号：US16622057

申请日：2018-12-06

Applicant: Korea Research Institute of Chemical Technology

Inventor： Kwangho Lee ,  Inji Shin ,  Gildon Choi ,  Chong Hak Chae ,  Hyeon Jeong Choe ,  Myoung Eun Jung ,  Byeong Uk Jeon ,  Byoung Chul Cho ,  Chae Won Park ,  Hwan Kim ,  Krishna Babu Duggirala

IPC: A61K31/506 ,  C07D413/12 ,  C07D401/14 ,  C07D413/14 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  A61P35/00

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.